Profil bibliographique

Mirco Pistelli

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

112Publications signalées

1409Citations signalées

2Affiliations récentes

Institutions déclarées

Marche Polytechnic University Ospedali Riuniti Umberto I

Domaines associés

Breast Cancer Treatment StudiesHER2/EGFR in Cancer ResearchCancer Treatment and PharmacologyAdvanced Breast Cancer TherapiesBRCA gene mutations in cancer

Publications récentes

Accès ouvert 2026 articleOpenAlex

Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER study

Letizia Pontolillo, Elisabetta Munzone, Paolo Vigneri, Mirco Pistelli et autres

1 citationThe Breast

Accès ouvert 2026 articleOpenAlex

Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival

Luigi Coltelli, Paola Orlandi, Chiara Finale, Gianna Musettini et autres

1 citationOncology Research Featuring Preclinical and Clinical Cancer Therapeutics

2025 articleOpenAlex

Comparison Between Alendronate and Denosumab in Preventing Bone Loss and Lowering Fracture Risk Related to Adjuvant Endocrine Therapy for Breast Cancer: Real-World Data From a Third-Level Center Experience

Claudio Gianfelice, Francesca Firmani, Gianmaria Salvio, Alessandro Ciarloni et autres

2 citationsEndocrine Practice

2025 conference-abstractOpenAlex

Abstract P3-12-07: SARELIFE study: Safety and efficacy of Sacituzumab Govitecan (SG) in pretreated metastatic triple negative breast cancer (mTNBC): a multicentric, real-life study

Elena Florio, Giovanna Catania, Elisa Gallerani, Giuliana D’Auria et autres

0 citationsClinical Cancer Research

Accès ouvert 2025 articleOpenAlex

Immunotherapy in Triple-Negative Breast Cancer

Elisa Tiberi, Alessandro Parisi, Mirco Pistelli, Agnese Savini et autres

16 citationsOncology and Therapy

Accès ouvert 2025 articleOpenAlex

New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2−Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and III

Nicola Battelli, Carmela Mocerino, Michele Montedoro, Mirco Pistelli et autres

1 citationCurrent Oncology

Accès ouvert 2024 articleOpenAlex

Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD Study

Eriseld Krasniqi, Lorena Filomeno, Teresa Arcuri, Francesca Sofia Di Lisa et autres

3 citationsCancers

Accès ouvert 2024 articleOpenAlex

Characteristics and clinical outcomes of breast cancer in young BRCA carriers according to tumor histology

Elisa Agostinetto, Marco Bruzzone, Anne‐Sophie Hamy, Hyo Jung Kim et autres

6 citationsESMO Open

2024 articleOpenAlex

390P SARELIFE: An Italian, multicentric real-world study of sacituzumab govitecan (SG) in pretreated metastatic triple-negative breast cancer (mTNBC)

Maria Silvia Cona, Lorenzo Ruggieri, Salvatore Artale, Giovanni Catania et autres

1 citationAnnals of Oncology

Accès ouvert 2023 articleOpenAlex

Pregnancy After Breast Cancer in Young BRCA Carriers

Matteo Lambertini, Eva Blondeaux, Elisa Agostinetto, Anne‐Sophie Hamy et autres

58 citationsJAMA

Accès ouvert 2023 articleOpenAlex

Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments

Carmine Valenza, Dario Trapani, Sara Gandini, Caterina Sposetti et autres

15 citationsEuropean Journal of Cancer

2023 conference-abstractOpenAlex

First line combination of ribociclib and letrozole in patients (pts) with metastatic breast cancer (MBC): Focus on hepatic toxicity in the context of a real–world setting the Italian, multicenter Hermione–8 study.

Francesca Piazza, Candida Bonelli, Stefania Lui, Camilla Di Nunzio et autres

1 citationJournal of Clinical Oncology

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.